These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 31766279)

  • 21. The role of P-glycoprotein in drug resistance in multiple myeloma.
    Abraham J; Salama NN; Azab AK
    Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies - A new era in the treatment of multiple myeloma.
    Jelinek T; Hajek R
    Blood Rev; 2016 Mar; 30(2):101-10. PubMed ID: 26362528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
    Yang WC; Lin SF
    Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proteasome inhibitors for the treatment of multiple myeloma.
    Scalzulli E; Grammatico S; Vozella F; Petrucci MT
    Expert Opin Pharmacother; 2018 Mar; 19(4):375-386. PubMed ID: 29478351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
    Iida S; Ri M
    Rinsho Ketsueki; 2014 Mar; 55(3):304-10. PubMed ID: 24681933
    [No Abstract]   [Full Text] [Related]  

  • 26. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
    Catley L; Tai YT; Chauhan D; Anderson KC
    Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.
    Magarotto V; Salvini M; Bonello F; Bringhen S; Palumbo A
    Leuk Lymphoma; 2016; 57(3):537-56. PubMed ID: 26445358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteasome inhibition and multiple myeloma.
    Kanagasabaphy P; Morgan GJ; Davies FE
    Curr Opin Investig Drugs; 2007 Jun; 8(6):447-51. PubMed ID: 17621873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mechanisms of drug resistance and sensitivity concerning novel agents for multiple myeloma].
    Tokuhira M
    Rinsho Ketsueki; 2016 May; 57(5):563-74. PubMed ID: 27263780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
    Zhu YX; Shi CX; Bruins LA; Wang X; Riggs DL; Porter B; Ahmann JM; de Campos CB; Braggio E; Bergsagel PL; Stewart AK
    Blood Cancer J; 2019 Feb; 9(2):19. PubMed ID: 30741931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.
    Yalnız FF; Akkoç N; Salihoğlu A; Ar MC; Öngören Ş; Eşkazan AE; Soysal T; Aydın Y
    Turk J Haematol; 2017 Aug; 34(3):233-238. PubMed ID: 28270368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug resistance in multiple myeloma.
    Robak P; Drozdz I; Szemraj J; Robak T
    Cancer Treat Rev; 2018 Nov; 70():199-208. PubMed ID: 30245231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P; Galán-Malo P; Marzo I; Naval J
    Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NF-κB dysregulation in multiple myeloma.
    Matthews GM; de Matos Simoes R; Dhimolea E; Sheffer M; Gandolfi S; Dashevsky O; Sorrell JD; Mitsiades CS
    Semin Cancer Biol; 2016 Aug; 39():68-76. PubMed ID: 27544796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Making precision oncology the standard of care.
    The Lancet Oncology
    Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma.
    Allegra A; Ettari R; Innao V; Bitto A
    Cells; 2021 Feb; 10(2):. PubMed ID: 33672466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy.
    Bosseler M; Marani V; Broukou A; Lequeux A; Kaoma T; Schlesser V; François JH; Palissot V; Berchem GJ; Aouali N; Janji B
    Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29882856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.